MX2024009216A - Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. - Google Patents

Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.

Info

Publication number
MX2024009216A
MX2024009216A MX2024009216A MX2024009216A MX2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A
Authority
MX
Mexico
Prior art keywords
enpp1
inhibitors
phosphodiesterase
ectonucleotide pyrophosphatase
ectonucleotide
Prior art date
Application number
MX2024009216A
Other languages
English (en)
Spanish (es)
Inventor
Feng Ren
Luoheng Qin
Yingtao Liu
Xin Cheng
Huaxing Yu
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of MX2024009216A publication Critical patent/MX2024009216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024009216A 2022-01-28 2023-01-28 Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. MX2024009216A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022074739 2022-01-28
CN2022140318 2022-12-20
PCT/CN2023/073579 WO2023143520A1 (en) 2022-01-28 2023-01-28 Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2024009216A true MX2024009216A (es) 2024-08-06

Family

ID=87470622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009216A MX2024009216A (es) 2022-01-28 2023-01-28 Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.

Country Status (12)

Country Link
US (1) US20250101019A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469456A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502943A (cg-RX-API-DMAC7.html)
KR (1) KR20240142481A (cg-RX-API-DMAC7.html)
CN (1) CN118871439A (cg-RX-API-DMAC7.html)
AR (1) AR128383A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023213905A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247162A1 (cg-RX-API-DMAC7.html)
IL (1) IL313821A (cg-RX-API-DMAC7.html)
MX (1) MX2024009216A (cg-RX-API-DMAC7.html)
TW (1) TW202340190A (cg-RX-API-DMAC7.html)
WO (1) WO2023143520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074128A1 (en) * 2022-10-08 2024-04-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025007955A1 (en) * 2023-07-06 2025-01-09 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) inhibitor combinations and uses thereof
CN121969621A (zh) * 2023-08-02 2026-05-01 英矽智能科技知识产权有限公司 外核苷酸焦磷酸酶-磷酸二酯酶1 (enpp1)抑制剂的结晶形式及其用途
WO2025026377A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912874A1 (en) * 1990-08-15 1992-02-26 British Bio Technology Compounds
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
CA2672327A1 (en) * 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
US20160222014A1 (en) * 2013-09-10 2016-08-04 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2019023635A1 (en) * 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
ES2960987T3 (es) * 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
WO2021061803A1 (en) * 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CA3204409C (en) * 2021-01-29 2026-04-28 Txinno Bioscience Inc. Benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof

Also Published As

Publication number Publication date
IL313821A (en) 2024-08-01
EP4469456A1 (en) 2024-12-04
KR20240142481A (ko) 2024-09-30
AR128383A1 (es) 2024-04-24
CN118871439A (zh) 2024-10-29
TW202340190A (zh) 2023-10-16
WO2023143520A1 (en) 2023-08-03
US20250101019A1 (en) 2025-03-27
JP2025502943A (ja) 2025-01-30
CA3247162A1 (en) 2023-08-03
AU2023213905A1 (en) 2024-07-11
EP4469456A4 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
MX2024005839A (es) Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos.
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SA522432955B1 (ar) Kras g12c مثبطات
MX2024003922A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos.
MX2019013954A (es) Inhibidores covalentes de kras.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
MX2025003515A (es) Moduladores de akt1
MX2025011086A (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
NZ797702A (en) Dual magl and faah inhibitors
MX2025000151A (es) Agonistas de trpml1 con oxazol y usos de los mismos
SA523440403B1 (ar) Magl مثبط
MX2022000811A (es) Inhibidores de enzimas.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
WO2024099364A3 (en) Fused multicyclic compounds and their use as parp1 inhibitors
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
CO2023012342A2 (es) Inhibidores de enzimas
JOP20220291A1 (ar) مثبطات جلوكوزيل سيراميدز غير متعلقة بالجسم الحال واستخداماتها
PH12022553031A1 (en) Akt3 modulators
AR121477A1 (es) Compuestos y métodos para el tratamiento de infecciones fúngicas
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors